An observational study in Coronary Artery Disease (CAD), Stable Angina Pectoris and Ischaemic Heart Disease (IHD), sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Queen Mary University of London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Coronary Artery Disease with a site in United Kingdom — 43 open to participants now, 73 under way, 6 of them phase 3. Coronary Artery Disease · United Kingdom.
Among the 283 studies in Coronary Artery Disease with a site in United Kingdom, this one is the 74th largest by planned enrollment of the 93 observational ones that give a count, is one of 14 that started in 2026, is one of 93 observational ones, reaches primary completion later than 60 of the 72 other live ones, and was the 282nd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →43 of the 283 studies in Coronary Artery Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
London North West Healthcare NHS Trust · Sites in United Kingdom
Ages 18+
EBI Anti Sepsis BV · Sites in United Kingdom, United States, Belgium and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–80
Queen Mary University of London · Sites in United Kingdom
Ages 40+
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 25 · Phase 3 28 · Phase 4 21
First in 1998; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 194 across the 190 interventional studies, 320 across the 93 observational. Of the 167 that completed or were terminated, 49 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 283 have an industry lead sponsor. The 10 most frequent:
Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.
Queen Mary University of London has 7 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Coronary Artery Disease with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357675Phase 3EBI Anti Sepsis BVA Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. | 2027-10-01 |
| NCT06951100University of EdinburghMechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation | 2026-12 |
| NCT04604782GE HealthcareA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | 2026-12 |
| NCT06185530London North West Healthcare NHS TrustSECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints | 2026-12-31 |
| NCT04286100London North West Healthcare NHS TrustContrast Specific Echocardiogram Versus Left Ventricular Opacification (LVO) Imaging Settings | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 283 studies in Coronary Artery Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK. Despite existing therapies, adverse cardiovascular events remains high, especially in patients who have already had a heart attack, as some of these patients have aggressive atherosclerotic disease. If we could identify these vulnerable patients, then in wider clinical practice in the future we might be able to treat them better with new therapies that can otherwise be expensive or come with a risk of side-effects. Traditionally, the assessment of atherosclerotic disease and the identification of the plaques that will cause heart attacks is performed using invasive imaging - imaging taken by passing a wire into the arteries of the heart that has a camera on its tip. Invasive imaging, however, can be used only in patients with symptoms and has risks. Photon counting (PC) CT is a new CT system that has image quality comparable to invasive imaging and can be used in the community to examine individuals with stable angina symptoms. In this study we aim to compare how well PC-CT detects high-risk plaques compared with invasive imaging and in due course develop a platform that will expedite the analysis of CT images to allow its broad use in the clinical practice.
Patients with a chronic coronary syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: observational study
Observation study comparing Photon-counting CT with intravascular coronary imaging in patients with chronic coronary syndrome
Compare the efficacy of PC-CTA and of conventional CTA in assessing the percent atheroma volume (PAV) using the output of the NIRS-IVUS analysis as the reference standard
Time frame: After each patient has had coronary angiography
Identify the optimal reconstruction method of PC-CTA data for measuring the PAV in the studied segment using the NIRS-IVUS estimations as the reference standard.
Time frame: After each patient has had coronary angiography.
Compare the accuracy of PC-CTA and conventional CTA in measuring flow patterns.
Time frame: After each patient has had coronary angiography.
Plan to share: Undecided
Started Aug 2026 (actual). Primary completion is estimated for Apr 2029, 31 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 31 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Mary University of London →